Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America

Michelle Weisfelner Bloom; Jacqueline B Vo; Jo E Rodgers; Alana M Ferrari; Anju Nohria; Anita Deswal; Richard K Cheng; Michelle M Kittleson; Jenica N Upshaw; Nicolas Palaskas; Anne Blaes; Sherry-Ann Brown; Bonnie Ky; Daniel Lenihan; Mathew S Maurer; Anecita Fadol; Kerry Skurka; Christine Cambareri; Ana Barac

doi:10.1016/j.cardfail.2024.08.046

Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America

J Card Fail. 2024 Oct 15:S1071-9164(24)00364-6. doi: 10.1016/j.cardfail.2024.08.046. Online ahead of print.

Authors

Michelle Weisfelner Bloom¹, Jacqueline B Vo², Jo E Rodgers³, Alana M Ferrari⁴, Anju Nohria⁵, Anita Deswal⁶, Richard K Cheng⁷, Michelle M Kittleson⁸, Jenica N Upshaw⁹, Nicolas Palaskas¹⁰, Anne Blaes¹¹, Sherry-Ann Brown¹², Bonnie Ky¹³, Daniel Lenihan¹⁴, Mathew S Maurer¹⁵, Anecita Fadol¹⁶, Kerry Skurka¹⁷, Christine Cambareri¹⁸, Ana Barac¹⁹

Affiliations

¹ Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY. Electronic address: [email protected].
² Radiation Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD.
³ Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC.
⁴ Division of Hematology/ Oncology, University of Virginia Health, Charlottesville, VA.
⁵ Cardio-Oncology Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
⁶ Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX.
⁷ Division of Cardiology, University of Washington, Seattle, WA.
⁸ Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
⁹ Division of Cardiology, Tufts Medical Center, Boston, MA.
¹⁰ Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
¹¹ Division of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, MN.
¹² Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Research Collaborator, Mayo Clinic, Rochester, MN.
¹³ Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Thalheimer Center for Cardio-Oncology, Abramson Cancer Center and Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
¹⁴ Saint Francis Healthcare, Cape Girardeau, MO and the International Cardio-Oncology Society, Tampa, FL.
¹⁵ Division of Cardiology, Columbia University Irving Medical Center, New York, NY.
¹⁶ MD Anderson Cancer Center, Houston, TX.
¹⁷ Cardio-Oncology Nurse/Program Consultant.
¹⁸ Clinical Oncology Pharmacist, Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.
¹⁹ Department of Cardiology, Inova Schar Heart and Vascular, Inova Schar Cancer, Falls Church, VA.

PMID: 39414560
DOI: 10.1016/j.cardfail.2024.08.046

No abstract available

Keywords: Heart failure; bone marrow/stem cell transplant; cancer; cancer treatment-related cardiac dysfunction; cardio-oncology; cardiomyopathy; cardiotoxicity; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; pulmonary.